MAAT INDEX

CLAIM #22802 · EMR (EMR) · 2025Q1 earnings call · Feb 5, 2025 · due Dec 31, 2025

We are ready to implement price and surcharges to protect the P&L commitments of the company. And these assumptions are embedded in our guide.

Lal Karsanbhai · CEO

PENDING
graded after results covering Dec 31, 2025 are reported

In context

rom China. At that time, we acted immediately to use price and surcharges to protect profitability and we also embarked on a program to de risk our supply chain for raw materials, sub-assemblies and finished goods. The impact of those tariffs was de minimis due to our swift actions and ability to capture price. The current tariff situation is fluid, but based on our supply chain regionalization strategy, learnings from prior tariff responses and planned price actions, we feel very good about our position. Starting with China, we do not expect a material impact based on actions taken since 2018. Next, we expect the impact from Canada to also be de minimis as we do not have any material exposure there. Last, the situation in Mexico is evolving and we are prepared for a variety of scenarios. We are ready to implement price and surcharges to protect the P&L commitments of the company. And these assumptions are embedded in our guide. Please turn to Slide 4. Q1 once again showcased Emerson’s ability to consistently execute. Underlying orders were up 1% year-over-year, led by healthy processing hybrid markets, which were up low-single digits despite a difficult comp from the prior year, which benefited from the timing of mega project bookings. Orders growth was led by robust demand in the Middle East and strength in the U.S., both from MRO business and several project awards. We saw exceptional demand growth in our power business, as well as continued strength in energy and energy transition projects globally. Chemical in the Middle East and Americas continues to see strong investment from capacity expansion and modernization efforts. Demand in China remained muted as strength in power was offset by weakness in chemical

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2025Q1 earnings call.